Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead 2vt Regulatory News (BMD)

Share Price Information for Baronsmead 2vt (BMD)

Share Price is delayed by 15 minutes
Get Live Data
45.00    0.00 (0.00%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £195.03m
BMD Live PriceLast checked at - London Stock Exchange

Intraday Baronsmead 2vt Share Chart

Interim Management Statement

19 May 2011 14:06

Baronsmead VCT3 plc Interim Management Statement

For the three month period from 1 January 2011 to 31 March 2011.

Headlines-

3.2% increase in underlying Net Asset Value per share £1.6 million investment in Valldata Group Limited Performance SummaryCapital return As at As at Movement 31 Mar 31 Dec 2011 2010 Total net assets £63.44m £64.64m* Net asset value per share 105.32p 102.10p* 3.2% Share price 93.13p 94.25p (1.2%) Discount to NAV (11.6%) (7.7%) Total return 3 months 1 year (%) 5 year (%) Since launch (%) (%) Net asset value(1) 3.0 14.7 18.7 85.6 Share price (2) 3.6 14.4 27.4 64.8 FTSE All-share (3) 1.0 8.7 20.0 42.4

*Stated after allowing for 4.5p final dividend for comparative purposes. NAV at 31st December 2010 excluding effect of dividend was 106.60p.

Key:

(1) NAV total return = NAV + reinvested dividends; Source: ISIS EP LLP

(2) Share price total return = Mid to mid share price + reinvested dividends; Source: AIC

(3) FTSE All-share = FTSE All-share Index + reinvested dividends; Source: AIC

These total returns are stated before the inclusion of VCT tax reliefs which are designed to mitigate the higher risks and costs associated with investing in smaller companies and the constraints of the VCT legislation. The tax reliefs given at the time of subscription have been 20%, 40% and later 30%, so any adjusted performance measure including this relief will vary depending on the date of subscription. There is the additional benefit of receiving VCT dividends tax free.

Investment Performance

Unquoted valuations have increased by 5.0% in the period bringing an uplift to the NAV per share and AIM-traded valuations increased by 1.3%. This increase compares favourably with the FTSE All-Share Index which increased by 1.0%.

Top ten Investments Position Position at Percentageat of NAV 31 Mar 2011 31 Dec 2010 Company as at 31 Mar 2011 1 1 Reed & Mackay 7.6 2 2 Nexus Vehicle Holdings Ltd 7.1 3 4 CableCom Networking Holdings Ltd 4.0 4 3 Crew Clothing Company Ltd 3.9 5 6 Quantix Limited 3.6 6 5 Kafevend Holdings Ltd 3.2 7 11 IDOX plc 3.1 8 7 Independent Living Services 3.0 9 9 CSC (World) Limited 2.9 10 8 Fisher Outdoor Leisure Holdings Ltd 2.8 Total 41.2Analysis of Total Assets Percentage of Percentage of total assets at total assets at 31 Mar 2011 31 Dec 2010 AIM, listed & collective investments 28 25 Unquoted investment 53 48 Interest bearing securities 16 25 Cash 3 2 Total cash portfolio 19 27 Total assets 100 100

Analysis of Investment Portfolio by Sector

(excluding cash and interest bearing securities)

Percentage of Percentage of total total investments investments at at 31 Mar 2011 31 Dec 2010 Business Services 37 36 Consumer Markets 19 18 Financial Services 2 2 Healthcare & Education 11 12 IT & Media 31 32 Total 100 100Investment Activity

During the quarter £1.62m was invested in a new unquoted company, Valldata Group Limited and further investment was made into three existing portfolio AIM-traded companies of £0.17m.

Wiltshire based Valldata is the UK's leading provider of outsourced donation processing and fulfilment services for the UK not-for-profit market. It uses its advanced technology and IT systems to handle large volumes of transactions covering paper based donations, donations via telephone and on-line services.

Investmentsmade Date Cost (£'000) Company Driver Group plc* Jan/Feb 2011 64 Netcall* Mar 2011 80 STM Group plc* Jan 2011 22 Valldata Services Ltd Jan 2011 1,616 Wood Street Microcap Investment Fund Jan 2011 700 Total Investment 2,482*Follow on investmentsRealisations Company Date Cost Proceeds Multiple (£'000) (£'000) x Craneware plc Mar 2011 72 298 4.2 MLS Mar 2011 42 42 1.0 Reed & Mackay Mar 2011 182 182 1.0 Total realisations 296 522

Net Asset Valueas at 30 April 2011.

The NAV per share at 30 April 2011 was 106.38p representing an increase of 1.0% since the quarter end.

Events after the period end

In April 2011 the investment in Reed & Mackay was sold achieving a net profit of £3.8 million on cash proceeds of £5.0 million. Including previous loan repayments and interest this represents a return of 4.76 times original cost and adds considerably to Baronsmead VCT 3's capacity to continue paying dividends to its shareholders in line with the stated dividend policy.

Fundraising

It is likely that the Company will undertake a further fundraising during the 2011/12 tax year. Further details will be sent to shareholders when the half yearly accounts to 30 June are published in August 2011.

Investment objective

Baronsmead VCT 3 plc is a tax efficient listed company which aims to achieve long-term investment returns for private investors.

Further information

Further information regarding the Company, including net asset values published since the end of the period and quarterly factsheets, can be found at the Company's website www.baronsmeadvct3.co.uk

Contact

For further information please contact:

Michael Probin Investor Relations Manager 020 7506 5600 michael.probin@isisep.com

vendor
Date   Source Headline
4th Jun 20263:15 pmRNSNet Asset Value(s)
3rd Jun 202610:15 amRNSNewsletter for the period June 2025 to March 2026
1st Jun 202611:26 amRNSTotal Voting Rights
18th May 20263:45 pmRNSAdmission of Further Securities to Trading
14th May 20262:15 pmRNSAllotment of Shares and Closure of Offer
11th May 20267:00 amRNSNet Asset Value(s)
5th May 20263:15 pmRNSNet Asset Value(s)
1st May 202611:42 amRNSTotal Voting Rights
8th Apr 202610:15 amRNSAdmission of Further Securities to Trading
1st Apr 202611:48 amRNSTotal Voting Rights
31st Mar 20265:37 pmRNSTransaction in Own Shares
30th Mar 20261:50 pmRNSNet Asset Value(s)
24th Mar 20262:25 pmRNSReplacement - Extension to Application Deadline
24th Mar 202612:20 pmRNSApplication Deadline Extension - Fourth Allotment
20th Mar 20267:00 amRNSResult of AGM
11th Mar 20262:00 pmRNSOver-Allotment Facility and Offer Update
5th Mar 20263:30 pmRNSNet Asset Value(s)
2nd Mar 202611:38 amRNSTotal Voting Rights
26th Feb 202612:15 pmRNSAdmission of Further Securities to Trading
20th Feb 202611:02 amRNSDirector/PDMR Shareholding
19th Feb 20264:30 pmRNSAllotment of Shares and Total Voting Rights
17th Feb 20264:05 pmRNSTransaction in Own Shares
6th Feb 202612:06 pmRNSOffer Update:Close of Early Subscription Incentive
5th Feb 20264:15 pmRNSNet Asset Value(s)
2nd Feb 20264:45 pmRNSNet Asset Value(s)
2nd Feb 202610:39 amRNSTotal Voting Rights
29th Jan 20263:35 pmRNSAdmission of Further Securities to Trading
22nd Jan 20263:40 pmRNSAllotment of Shares and Total Voting Rights
12th Jan 202611:35 amRNSPublication of a Supplementary Prospectus
23rd Dec 20257:00 amRNSAnnual Financial Report
23rd Dec 20257:00 amRNSAnnual Financial Report
4th Dec 20253:45 pmRNSNet Asset Value(s)
1st Dec 202510:44 amRNSTotal Voting Rights
20th Nov 20251:22 pmRNSDirector/PDMR Shareholding
20th Nov 202512:00 pmRNSAllotment of Shares and Total Voting Rights
6th Nov 20254:00 pmRNSNet Asset Value(s)
29th Oct 20259:45 amRNSNet Asset Value(s)
13th Oct 20252:00 pmRNSPublication of a Prospectus/Offer for Subscription
1st Oct 20257:00 amRNSTotal Voting Rights
29th Sep 20255:56 pmRNSTransaction in Own Shares
24th Sep 20258:46 amRNSUpdate on Offer for Subscription
23rd Sep 20252:49 pmRNSQuarterly Factsheet June 2025 & Newsletter H2 2025
11th Sep 20256:06 pmRNSTransaction in Own Shares
11th Sep 20255:09 pmRNSDirector/PDMR Shareholding
4th Sep 20253:15 pmRNSNet Asset Value(s)
4th Sep 20258:15 amRNSIntention to Fundraise
6th Aug 20254:15 pmRNSNet Asset Value(s)
31st Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 202510:00 amRNSNet Asset Value(s)
1st Jul 20255:13 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.